Centene Stock Plunges 40% to an 8-Year Low—Watch These Key Price Levels

Centene (CNC) shares plunged 40% on Wednesday, closing at their lowest level since 2017, after the managed-care company withdrew its full-year outlook. This decision stemmed from new data indicating slower enrollment growth and significantly higher patient illness than anticipated, which is projected to impact 2025 results by $1.8 billion, or $2.75 in adjusted earnings per share, due to lower federal reimbursements and increased costs. The sharp decline, occurring on above-average volume and pushing the stock below its 200-month moving average, underscores strong selling conviction and extends a downtrend that has seen Centene lose two-thirds of its value since August 2022.

Analysis

Centene has experienced a severe fundamental and technical breakdown following the withdrawal of its full-year outlook, a decision driven by new data revealing slower enrollment and significantly higher member health costs. The financial repercussions are substantial, with the company projecting a $1.8 billion impact on 2025 results, equivalent to a $2.75 reduction in adjusted earnings per share, due to anticipated lower federal reimbursements and increased medical expenses. The market's reaction was immediate and punitive, with shares plummeting 40% to their lowest level since 2017 on above-average volume, signaling strong selling conviction. This event has accelerated a long-term downtrend that has pushed the stock price below its critical 200-month moving average and erased two-thirds of its value from its August 2022 peak. While the relative strength index now indicates oversold conditions, the underlying issues of rising medical costs and declining enrollments, which also affect industry peers, suggest a challenging operating environment ahead.

Key Decisions for Investors

• Given the withdrawal of guidance and the significant projected earnings impact for 2025, a bearish or at-minimum cautious stance is warranted, as the 40% price decline reflects a severe deterioration in company fundamentals.
• Investors should closely monitor the technical support levels at $27 and $17 for signs of stabilization or further breakdown, while recognizing that any near-term bounce from oversold conditions will likely face significant resistance around the $42 level.
• A long-term investment thesis is challenged by the fundamental issues, and any consideration of a position should be deferred until there is clear evidence of stabilization in medical cost trends and enrollment figures.